Actively Recruiting
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications
Led by Tethis S.p.A. · Updated on 2026-01-30
45
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the feasibility of using See.d instrument and SBS slides for preparation of plasma and cytological samples from whole blood. Forty-five participants will be enrolled (20 healthy volunteers and 25 metastatic breast cancer patients) and each participant will be asked to provide a blood sample.
CONDITIONS
Official Title
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants is willing and able to give and sign a written informed consent
- Aged 18 or above
- Female metastatic breast cancer patients aged 18 or above
- Histological confirmation of breast cancer
- Presence of at least one non-bone metastasis
- Disease in clinical or radiologic progression to the last line of treatment as evaluated by the investigator
- Biopsy scheduled within 4 weeks after blood withdrawal when recommended
- Last biopsy or minor surgery performed at least 7 days before blood withdrawal
- Known bilirubin level 6 2 mg/dL on blood sample collected within 7 days from enrolment (if unavailable, bilirubin assessment not necessary)
- Healthy volunteers of both sexes aged 18 or above
- Healthy participants visiting site for reasons other than cancer diagnosis (including breast cancer)
You will not qualify if you...
- Ongoing infections requiring antibiotic or antiviral treatment
- Previous history of blood cancer or invasive non-breast cancer except curatively treated cancers with no recurrence for at least 3 years (including breast cancer for healthy participants)
- Major surgery within 4 weeks prior to blood collection
- Initiated new treatment line after disease progression at time of blood or tissue biopsy collection
- Known severe coagulation or hematological disorder
- Pregnancy
- For metastatic breast cancer patients: histological confirmation of Triple Negative Breast Cancer (TNBC)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IEO
Milan, Italy, 20132
Actively Recruiting
Research Team
L
Luca Mazzarella, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here